← Eichor
Study identifier: NCT06963268 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Validation of the Sentinel Lymph Node Technique in Early-stage Ovarian Cancer (SENTOV II)

Condition: Ovarian Neoplasms  ·  Sponsor: Instituto de Investigacion Sanitaria La Fe

PhasePhase 3
Planned participants200
Who can joinFemale, 18 Years to no upper limit
Healthy volunteersNo

About this study

This clinical trial investigates the sentinel lymph node (SLN) technique as a less invasive alternative to conventional lymphadenectomy in patients with early-stage ovarian cancer. The primary objective is to evaluate the effectiveness, safety, and diagnostic accuracy of the SLN approach in detecting lymphatic metastases. By assessing its negative predictive value, the study aims to determine whether the SLN technique can reliably replace systematic pelvic and paraaortic lymphadenectomy. If successful, this technique could minimize surgical morbidity, shorten hospitalization stays, and lower complication rates, ultimately improving patient outcomes.

This description comes directly from the study's public registry record.

Talk to the study team

Mónica Cebrián Coordinator Clinical Research Area  ·  +34961246731  ·  investigacion_clinica@iislafe.es

Always discuss trial participation with your own doctor first.

Locations (1)

Hospital Universitario y Politécnico La FeValencia, Valencia, SpainRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06963268